Menu
Search
|

Menu

Close
X

Innovate Biopharmaceuticals Inc INNT.OQ (NASDAQ Stock Exchange Capital Market)

4.90 USD
-0.10 (-2.00%)
As of Feb 24
chart
Previous Close 5.00
Open 5.04
Volume 1,221
3m Avg Volume 4,665
Today’s High 5.04
Today’s Low 4.90
52 Week High 23.50
52 Week Low 3.43
Shares Outstanding (mil) 9.34
Market Capitalization (mil) 5.77
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY17
1
FY16
4
FY15
8
EPS (USD)
FY17
-0.635
FY16
-0.811
FY15
-1.084
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
1.94
5.77
Price to Book (MRQ)
vs sector
--
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
--
16.52
LT Debt to Equity (MRQ)
vs sector
--
12.22
Return on Investment (TTM)
vs sector
--
14.43
Return on Equity (TTM)
vs sector
--
16.13

EXECUTIVE LEADERSHIP

Sandeep Laumas
Executive Chairman of the Board, Since 2018
Salary: --
Bonus: --
Jay Madan
President, Director, Since 2018
Salary: --
Bonus: --
Christopher Prior
Chief Executive Officer, Director, Since 2018
Salary: --
Bonus: --
Lorin Johnson
Independent Director, Since 2018
Salary: --
Bonus: --
Anna Kazanchyan
Independent Director, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

8480 Honeycutt Rd Ste 120
RALEIGH   NC   27615-2261

Phone: +1919.2751933
Site:

Innovate Biopharmaceuticals, Inc., formerly Monster Digital, Inc., is a clinical stage biotechnology company. The Company is focused on developing novel autoimmune and inflammation therapeutic drugs. Its lead drug candidate, larazotide acetate (INN-202) is a tight junction regulator. Its other products include INN-108 and INN-329 (Secretin). The Company’s INN-108 is a novel small molecule comprised of two active parts with anti- inflammatory and immunodulatory properties coupled through an azo bond. The Company is developing INN-108 as a therapeutic for Ulcerative Colitis (UC). Its Secretin stimulated magnetic resonance cholangiopancreatography (MRCP) is a ionizing, radiation-free assessment of the pancreaticobiliary system. The Company has completed a phase II b clinical trial for celiac disease for INN-202. It is developing INN-108 in a phase II trial for inflammatory bowel disorders, mild to moderate UC and a Gastrointestinal (GI) orphan disease.

SPONSORED STORIES